ROTH

It's a Done Deal

$28,150,000

CapsoVision

IPO

Joint Book-Running Manager

JULY 2025

Roth Capital Partners acted as Joint Book-Running Manager for CapsoVision, Inc. (NASDAQ: CV) in its recent $28.2 Million IPO

For more information please contact:

Investment Banking
Benjamin Bowen
Managing Director,
Investment Banking
(646) 716-3607
bbowen@roth.com

Equity Capital Markets
Aaron Gurewitz
President & Head of
Investment Banking
(949) 720-5703
agurewitz@roth.com

Nazan Akdeniz
COO &
Managing Director
Equity Capital Markets
(949) 720-5740
nakdeniz@roth.com

Lou Ellis
Managing Director
Equity Capital Markets
(949) 720-5739
lellis@roth.com

Transaction Information
CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025.

CapsoVision received gross proceeds from the offering of approximately $28.2 million as the underwriters' over-allotment option was partially exercised, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Roth Capital Partners acted as Joint Book-Running Manager for the offering.

About CapsoVision, Inc.
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company's next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information, please visit www.capsovision.com. *(Source: Company Press Release 7.03.25)*

About Roth Capital Partners
Roth Capital Partners, LLC ("ROTH") is a relationship-driven investment bank focused on serving growth companies and their investors. Our full

service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, Roth is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit www.roth.com.

Date of Announcement: 07.24.25

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com